PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results
CompaniesPolyPidAzurity PharmaceuticalsAssetsD-PLEX₁₀₀Diseasessurgical site infections
Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
CompaniesNeurocrine BiosciencesAssetsNBIP-'1968Diseasesobesity
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
CompaniesNeurocrine BiosciencesAssetsINGREZZAvalbenazineDiseasestardive dyskinesia
Syneos Health Advances AI-Powered Clinical Ecosystem to Optimize Trial Performance and Speed Decision-Making
CompaniesSyneos Health
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
CompaniesDaré Bioscience
DLH to Provide Mission-Critical Cyber Support for U.S. Navy
CompaniesDLH Holdings Corp.
Coloplast A/S - Interim Financial Report, 9M 2025/26
CompaniesColoplast A/S
U.S. Oral Surgery Management Partners with Cottonwood Oral & Maxillofacial Surgery of Albuquerque
CompaniesU.S. Oral Surgery ManagementCottonwood Oral & Maxillofacial Surgery
Ketogenic Foundation Announces 2026 Conference Exploring the Future of Metabolic Health and Chronic Disease Care
CompaniesKetogenic Foundation
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
CompaniesNeOnc Technologies
Jabra Enhance introduces a new lineup of FDA-cleared self-fitting hearing aids, 3 new models with improved hearing technology and in-app self-tuning
CompaniesJabra EnhanceAssetsEnhance Select M3Enhance Select M2Enhance Select M1
Hoag First in California to Bring Radiation-Reducing Technology to Complex Vascular Care
CompaniesHoag
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CompaniesImageneBio, Inc.
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
CompaniesCoherus OncologyAssetsLegacy Biosimilar Assets
Basilea erzielt starkes Halbjahresergebnis 2026 und erhöht die Finanzprognose für das Gesamtjahr; Phase-3-Programm mit Fosmanogepix auf Kurs
CompaniesBasilea Pharmaceutica International Ltd
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
CompaniesBasilea Pharmaceutica International LtdAssetsCresembaZevterafosmanogepixceftibuten-ledaborbactamBAL2420BAL2062Diseasesinvasive fungal infectionsbacterial infectionsinvasive yeast and mold infectionscomplicated urinary tract infections
Asimov Announces Cell Line Development Partnership with Kaigene to Advance Multispecific Antibody for Autoimmune Disease
CompaniesAsimovKaigeneAssetsmultispecific antibodyDiseasesautoimmune disease
Immatics Announces Second Quarter 2026 Financial Results and Business Update
CompaniesImmatics N.V.
CHARM Therapeutics announces formation of Clinical Advisory Board to support advancement of CHM-029, its next-generation menin inhibitor
CompaniesCHARM TherapeuticsAssetsCHM-029Diseasesacute myeloid leukemia
General Oncology Nominated for the 2026 Prix Galien USA Best Startup Award
CompaniesGeneral OncologyAssetsGO-4Diseasesstage IV pancreatic ductal adenocarcinomastage IV HER2-negative breast cancer